LTR Pharma (ASX:LTP) Buyback Yield %: 0.00 (As of Jun. 30, 2026)


ASX:LTP LTR Pharma Ltd ASX:LTP
15 GF Score
Price A$0.55
View Full Analysis

What is LTR Pharma Buyback Yield %?

LTR Pharma ASX:LTP -6.03% 15 Buyback Yield % is 0.00 as of Jun. 30, 2026. GuruFocus rates ASX:LTP with a GF Score™ of 15/100. Among 742 Biotechnology companies, LTR Pharma ranks worse than 134770.75% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

LTR Pharma's current buyback yield was 0.00%.

LTR Pharma Buyback Yield % Historical Data

* Premium members only.

The historical data trend for LTR Pharma's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LTR Pharma Buyback Yield % Chart

LTR Pharma Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
Buyback Yield %
0.00 0.00 0.00 -5.97 -63.58

LTR Pharma Semi-Annual Data
Jun21 Jun22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Buyback Yield % Get a 7-Day Free Trial -13.51 -5.97 -22.76 -63.58 0.00

ASX:LTP vs VRTX, REGN, ALNY: Buyback Yield % Comparison

For the Biotechnology subindustry, LTR Pharma's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LTR Pharma Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LTR Pharma's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where LTR Pharma's Buyback Yield % falls into.


ASX:LTP
15GF Score
LTR Pharma Ltd ASX:LTP
Buyback Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

LTR Pharma Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

LTR Pharma's Buyback Yield for the fiscal year that ended in Jun. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (-2.13 + 35.5) / 52.48362
=-63.58%

LTR Pharma's annualized Buyback Yield for the quarter that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 0) / 130.7844
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of 0.00 mean?
LTR Pharma (ASX:LTP) has a Buyback Yield % of 0.00 as of Jun. 30, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on LTR Pharma and its competitors. According to the industry distribution chart, LTR Pharma ranks #999999 out of 742 companies in the Biotechnology industry.
Is LTR Pharma's Buyback Yield % too high?
LTR Pharma's current Buyback Yield % is 0.00. Based on the distribution chart, LTR Pharma ranks #999999 out of 742 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, LTR Pharma has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does LTR Pharma's Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, LTR Pharma ranks #999999 out of 742 companies for Buyback Yield %. This places LTR Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on LTR Pharma and its competitors. LTR Pharma's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LTR Pharma stock overvalued right now?
LTR Pharma (ASX:LTP) has a current Buyback Yield % of 0.00. The current Buyback Yield % is 0.00. LTR Pharma's overall GF Score™ is 15/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For LTR Pharma (ASX:LTP), the current Buyback Yield % is 0.00 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LTR Pharma Business Description

Address 9A/204 Alice Street, Brisbane, QLD, AUS, 4000
LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on the market.
15GF Score

Get the complete analysis for ASX:LTP

Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.55
Price